To estimate prevalence of hepatitis C virus (HCV) infection and identify risk factors associated and circulating HCV genotypes and subtypes.
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INTRODUCTION
Hepatitis C virus (HCV) infection is a major public health concern. It is estimated that 2.2% of the world's population, around 130 million people, are infected with HCV. 1 Acute hepatitis C is often asymptomatic but it is a major cause of morbidity and mortality as most cases progress to chronic disease and can lead to liver cirrhosis and hepatocellular carcinoma.
HCV genoma is characterized by high genetic variability. Six genotypes and multiple subtypes have been identifi ed and they show different response to antiviral therapy as well as diverse geographical distribution. Genotypes 1, 2 and 3 are disseminated worldwide. Genotype 4 is more prevalent in North Africa and Middle East. HCV infections with genotypes 5 and 6 are commonly seen in South Africa and Asia, respectively. 24 In Brazil, studies have demonstrated that genotype 1 is the most prevalent, followed by genotype 3. 5, 18 Hepatitis C transmission most effectively occurs through the parenteral route, transfusion and/or exposure to blood and blood products, but can also be less effectively transmitted through sexual contact and from mother to child. 1 Drug users (DU) have an increased risk of HCV infection due to sharing of injecting materials and unsafe sex practices. 12, 13, 16, 23 There are few Brazilian studies investigating HCV infection in DU including both injecting and noninjecting drug users. Their HCV prevalence rates range from 5.8% to 36.2%. 2, 7, 10, 19, 23 The present study is the fi rst to investigate HCV infection in illicit DU with the objective of estimating the prevalence of and factors associated with HCV infection and identifying circulating HCV genotypes and subtypes.
METHODS
A cross-sectional study was conducted in a convenience sample drawn from patients attending all charitable, private and public drug treatment centers in the municipalities of Goiânia and Campo Grande, central-western Brazil, between August 2005 and July 2006. There were selected 851 users, 542 from 18 centers (ten to 70 patients per center) in Goiânia and 309 from eight centers (ten to 76 patients per center) in Campo Grande. All subjects were informed on the study objectives and procedures and invited to participate. The following inclusion criteria were applied: 18 years of age or more; injecting and/or non-injecting drug use; and enrollment in a drug treatment center. All patients agreed to participate in the study. Injecting drug users (IDU) were defi ned as those patients reporting intravenous drug use; and non-injecting drug users (NIDU) were defi ned as those patients who reported never using intravenous drugs and reported lifetime use of marijuana, cocaine (powder, crack, and "merla"), heroin, LSD, and ecstasy through other routes (sniffi ng, smoking, and ingestion). Of 851 users, 691 (81.2%) were eligible to participate in the study, of which were 102 IDU and 589 NIDU.
A standardized questionnaire based on the World Health Organization (WHO) recommendations 8 was applied to all subjects and data was collected on sociodemographic characteristics (age, sex, marital status, skin color, schooling, and family income) and potential risk factors for HCV infection (route of administration and length of time of drug use, prior blood transfusion/year of fi rst transfusion and surgery, tattoos/piercing, acupuncture, condom use, number of sexual partners, IDU partner, history of sexually transmitted disease [STD] and prior imprisonment). Then 10 ml blood was drawn from each subject and sera were stored at -20°C.
All samples were tested for HCV antibodies (anti-HCV, Hepanostika Ultra, Biomedical, China) using enzymelinked immunosorbent assay (ELISA). Positive samples for the marker anti-HCV were confi rmed by immunoblot (Bioblot HCV, Biokit, Spain).
Anti-HCV positive samples were submitted to RNA extraction, reverse transcription, and polymerase chain reaction (PCR), with primers complementary to noncoding (NC) regions of the virus genoma, as described by Ginabreda et al 11 (1997) . RNA HCVpositive samples were genotyped by line probe assay (LiPA -Versant HCV Genotype Assay, Innogenetics, Belgium).
The phylogenetic analysis of the NS5B region of the virus genoma was performed by confirming HCV genotypes and subtypes. cDNA samples obtained by reverse transcription were amplifi ed by PCR with primers under the same conditions as described by Sandres-Sauné et al 22 (2003) . PCR products were then purifi ed using the QIAquick Gel Extraction kit (Qiagen, GmbH, Hilden, Germany) and submitted to direct nucleotide sequencing in both directions using the BigDye Terminator kit (version 3.1, Applied Biosystems, Foster City CA, USA) and analyzed in an ABI-3730 sequencer (Applied Biosystems). The sequences obtained containing 340 nucleotides (from position 8279 to 8619 of the virus genoma) were aligned using ClustalX program. 25 A phylogenetic tree was constructed with a neighbor-joining method using software Mega 2.1, 14 and the Kimura 2-parameter model. Reliability of clusters of the phylogenetic tree was assessed using the bootstrap test based on 1,000 pseudoreplicates. Genotypes and subtypes of HCV samples were identifi ed by adding in the phylogenetic analysis reference sequences representative of the main HCV genotypes/subtypes available in Genbank (referred in the phylogenetic tree by subtype, followed by the number of access to Genbank).
Data analysis was carried out using Epi Info program version 2000. Prevalences and odds ratios (OR) were calculated with 95% confi dence intervals (95% CI). Risk factors with p< 0.10 in the univariate analysis were then analyzed by hierarchical logistic regression using SPSS program version 11.0 to identify potential confounders. χ 2 test for association, χ 2 test for tendency and Fisher's exact test were also performed. A 5% signifi cance level was set.
The study was approved by the Research Ethics Committee of Hospital Materno Infantil (Mother-Child Hospital) (Protocol No. 004/05) in Goiânia. All subjects signed a free informed consent.
RESULTS
Mean age of the sample studied was 28.3 years (SD= 9.0), 88.3% were males, 64.3% single, 59.5% white, 70.2% reported up to eight years of schooling and 46.5% reported family income between two and fi ve monthly minimum wages. Most used two or more non-injecting drugs. The main drug consumed were marijuana (82.9%), powder cocaine (59.6%), "merla" cocaine (52.8%), and crack (37.9%).
Of 691 drug users studied, anti-HCV marker was detected in 49 (7.1%) blood samples. Of these, 48 were positive by immunoblot, showing a 6.9% prevalence of anti-HCV (95% CI: 5.2;9.2) ( (Figure) .
The univariate analysis showed that HCV infection was signifi cantly associated to age, marital status, family income, route of administration and length of time of drug use, prior blood transfusion and surgery, IDU partner, and history of STD ( Table 2 ). The multiple Figure. Phylogenetic tree of the NS5B region, including isolates of drug users and GenBank sequences of genotypes 1 to 6 represented by the main subtypes of hepatitis C virus. (Table 3) .
DISCUSSION
The present study has limitations that should be considered in the interpretation of results. The number of DU and their general characteristics in the cities of Goiânia and Campo Grande are not actually known since drug use is an illicit activity. For that reason, HCV infection was only investigated among those IDU and NIDU enrolled in charitable, private, and public drug treatment centers during the study period. On the other hand, given the scarcity of epidemiological data about HCV infection among DU in the cities studied, our results provide background information for formulating policies and strategies for reducing risk and damage associated to the use of illicit drugs. 10, 19, 23 This inconsistency can be explained by the greater proportion of IDU in the samples of the latter studies compared to the former ones (22%-27% versus 10%-15%).
The investigation of HCV RNA reveals those individuals who are HCV carriers, especially in high-risk groups such as drug users. In the present study, of 48 subjects with anti-HCV positive, 41 were HCV RNApositive, showing a high rate of viremia (85.4%). This fi nding shows that drug users are thus major HCV carriers and potential transmitters, which is corroborated by other studies. 10, 13 All 41 samples HCV-RNA positive were genotyped by LiPA, and genotype 1 was found to be the most prevalent, followed by genotype 3. Similar results were demonstrated in IDU in the city of Rio de Janeiro, 20 and these same genotypes are the most prevalent in Brazil, 5 as well in central-western region. 18 Subtypes 1a (63.4%), followed by 3a (19.5%) and 1b (17.1%) were the most predominant. The 5' NC region, as it is the most preserved in the virus genoma, could be amplifi ed by PCR in a large number of samples genotyped. That is why the 5' NC region is often investigated for HCV detection and genotyping, especially for the clinical purpose of choosing the best therapeutic regimen for viral hepatitis C. 9 A similar distribution was seen for subtypes 1a, 3a, and 1b in the phylogenetic analysis of the NS5B region (68%, 20%, and 12%, respectively). There is no inconsistency between genotypes and subtypes of 25 samples tested by both methods. Although both methods are as effective for genotyping, inconsistent results between HCV subtypes have been reported in other studies. Some authors 9, 15, 22 believe that the NS5B region is more adequate for subtyping that the 5' NC region, which is too preserved and cannot differentiate some subtypes, especially 1a and 1b. Hence, the phylogenetic analysis of the NS5B region is more adequate to identify HCV in epidemiological studies and was used to confi rm HCV genotypes and subtypes in the sample studied.
In the present study, age over 30 years was associated to HCV infection (OR=16.0; 95% CI: 3.9;66.0), which is consistent with other studies investigating illicit drug users. 12, 16, 21 This association can be explained by higher risk of virus exposure during their lifetime.
IDU subjects were more likely to have HCV infection (OR= 18.0, 95% CI: 6.9;47.1) compared to NIDU. In addition, HCV prevalence was nearly 12-fold greater in IDU than NIDU (31.4% versus 2.7%, Table 2 ). Higher risk for hepatitis C infection in IDU compared to NIDU also was reported by several authors, 2, 7, 10, 13, 23 which corroborates the fi nding of effi cient HCV transmission through parenteral route. There was seen a tendency for the association between prior blood transfusion and HCV infection. This association has been reported especially in blood transfusions before the implementation in Brazil of anti-HCV screening in blood banks in November 1993. 4, 6 In fact, in the present study, among 14 anti-HCV positive subjects who had prior blood transfusion, most of them took place prior to this date (data not shown), stressing the importance of anti-HCV screening in blood banks in Brazil.
It was also observed an association between HCV infection and anti-HBc (χ 2 = 20.2; p<0.05; data not shown), a marker of HBV exposure. This fi nding with potential clinical and epidemiological relevance corroborates the fi ndings of other authors investigating drug users, 21, 23 and suggests common transmission forms of HBV and HCV in DU.
In conclusion, the present study evidenced high prevalence of HCV infection and subtype 1a among illicit drug users. It was also found that injecting drug use is a major risk factor for HCV infection. This data, associated to the progress to chronic infection, low response of genotype 1 to antiviral therapy and unavailability of a hepatitis C vaccine, reinforces the need for effective programs for prevention and control of hepatitis C among illicit drug users.
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